Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

ACORDA THERAPEUTICS INC (ACOR)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
26.05(c) 26.65(c) 27.05(c) 26.7(c) 27.2(c) Last
509 954 473 303 655 780 464 373 618 911 Volume
+0.77% +2.30% +1.50% -1.29% +1.87% Change
More quotes
Financials ($)
Sales 2017 569 M
EBIT 2017 73,8 M
Net income 2017 26,8 M
Debt 2017 128 M
Yield 2017 -
Sales 2018 433 M
EBIT 2018 -20,3 M
Net income 2018 -19,4 M
Debt 2018 117 M
Yield 2018 -
P/E ratio 2017 53,46
P/E ratio 2018
EV / Sales2017 2,46x
EV / Sales2018 3,20x
Capitalization 1 269 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
10/12 ACORDA THERAPEUTICS : Data on Nerve Growth Factors Reported by Researchers at Ac..
10/10 ACORDA THIRD QUARTER 2017 UPDATE : Webcast/Conference Call Scheduled for October..
09/28 ACORDA THERAPEUTICS,INC. (NASDAQ : ACOR) Files An 8-K Other Events
09/25 ACORDA THERAPEUTICS Faruqi & Faruqi, LLP Encourages Investors Who Suffered Lo..
09/21 ACORDA THERAPEUTICS : to Present at the Cantor Fitzgerald Global Healthcare Conf..
09/21 ACORDA THERAPEUTICS : Patent Issued for Methods for Detecting Cardiac Damage (US..
09/13 ACORDA THERAPEUTICS : to Present at the Cantor Fitzgerald Global Healthcare Conf..
09/08 Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.
09/07 ACORDA THERAPEUTICS, INC. INVESTOR A : Legal Investigation for Potential Securit..
09/07 Investigation of Acorda Therapeutics Announced by Holzer & Holzer
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/20Acorda Therapeutics, Inc. $ACOR Stock Rating Upgraded by Zacks Investment Res.. 
10/20Advaxis : Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Ac.. 
10/20TIAA CREF Investment Management LLC Has $4.38 Million Stake in Acorda Therape.. 
10/18Acorda Therapeutics upgraded by Zacks Investment Research to hold.  
10/17$ACOR - Acorda Therapeutics, Inc. #ACOR Given Average Rating of "Hold" by Ana.. 
More tweets
Qtime:126
News from SeekingAlpha
10/12 YOUR DAILY PHARMA SCOOP : AcelRx DSUVIA PDUFA, Ardelyx Phase 3 Success, Rhopress..
10/10 YOUR DAILY PHARMA SCOOP : Synergy's Cash Position, Flexion's Zilretta Approval, ..
09/29 YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou..
09/28 ACORDA : Setback And Opportunity
09/04 Faison's Weekend Review And Scans
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Technical analysis trends ACORDA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 22,7 $
Spread / Average Target -16%
EPS Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
Andrew R. Blight Chief Scientific Officer
Richard P. Batycky Chief Technology Officer
Burkhard Blank Chief Medical Officer
Sandra Panem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS INC43.88%1 269
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912